Abstract：
UNASSIGNED: Ampicillinase C beta-lactamase-producing organisms are often resistant to multiple antimicrobial agents, and therapeutic options against these pathogens are limited. Limited information is available regarding Ampicillinase C beta-lactamase producers. The aim of this study was to find out the prevalence of Ampicillinase C beta-lactamase producers among isolates of Enterobacteriaceae in a tertiary care centre.
UNASSIGNED: A descriptive cross-sectional study was carried out in the Clinical Microbiology Laboratory of a tertiary care centre from May 2021 to October 2021. Ethical approval was received from the Institutional Review Committee (Reference number: 044-077/078). Isolates of Enterobacteriaceae from various clinical samples were collected by convenience sampling. Ampicillinase C screening for beta-lactamase producers among the Enterobacteriaceae isolates was done using cefoxitin (30 μg) disc. Detection of Ampicillinase C beta-lactamase producers among the screen-positive isolates was done by cefoxitin-cloxacillin double-disc synergy test. An increase in the zone size of ≥4 mm was considered as Ampicillinase C beta-lactamase producers. Point estimate and 95% Confidence Interval were calculated.
UNASSIGNED: Among the total 481 isolates of Enterobacteriaceae, 49 (10.19%) (7.50-12.90, 95 % Confidence Interval) were detected as Ampicillinase C beta-lactamase producers among isolates of Enterobacteriaceae.
UNASSIGNED: The prevalence of Ampicillinase C beta-lactamase producers was lower than in other studies done in similar settings. Meropenem could be a drug of choice for the treatment of infections due to Ampicillinase C beta-lactamase-producing gram-negative bacteria.
UNASSIGNED: antibiotic; beta-lactamase; Enterobacteriaceae; gram-negative bacteria.
UNASSIGNED: A descriptive cross-sectional study was carried out in the Clinical Microbiology Laboratory of a tertiary care centre from May 2021 to October 2021. Ethical approval was received from the Institutional Review Committee (Reference number: 044-077/078). Isolates of Enterobacteriaceae from various clinical samples were collected by convenience sampling. Ampicillinase C screening for beta-lactamase producers among the Enterobacteriaceae isolates was done using cefoxitin (30 μg) disc. Detection of Ampicillinase C beta-lactamase producers among the screen-positive isolates was done by cefoxitin-cloxacillin double-disc synergy test. An increase in the zone size of ≥4 mm was considered as Ampicillinase C beta-lactamase producers. Point estimate and 95% Confidence Interval were calculated.
UNASSIGNED: Among the total 481 isolates of Enterobacteriaceae, 49 (10.19%) (7.50-12.90, 95 % Confidence Interval) were detected as Ampicillinase C beta-lactamase producers among isolates of Enterobacteriaceae.
UNASSIGNED: The prevalence of Ampicillinase C beta-lactamase producers was lower than in other studies done in similar settings. Meropenem could be a drug of choice for the treatment of infections due to Ampicillinase C beta-lactamase-producing gram-negative bacteria.
UNASSIGNED: antibiotic; beta-lactamase; Enterobacteriaceae; gram-negative bacteria.
摘要：
未经证实：产生氨苄酶Cβ-内酰胺酶的生物通常对多种抗菌药物具有耐药性，和治疗这些病原体的选择是有限的。关于氨苄酶Cβ-内酰胺酶生产者的信息有限。这项研究的目的是在三级护理中心的肠杆菌科分离株中找出氨苄酶Cβ-内酰胺酶生产者的患病率。
UNASSIGNED：一项描述性横断面研究于2021年5月至2021年10月在三级护理中心的临床微生物学实验室进行。从机构审查委员会收到伦理批准(参考号:044-077/078)。通过方便取样收集来自各种临床样品的肠杆菌科分离物。使用头孢西丁（30μg）圆盘在肠杆菌科分离株中筛选β-内酰胺酶生产者。通过头孢西丁-氯唑西林双盘协同作用试验，在筛选阳性分离株中检测氨苄酶Cβ-内酰胺酶生产者。≥4mm的区域大小的增加被认为是氨苄酶Cβ-内酰胺酶的生产者。计算点估计和95%置信区间。
未经证实：在总共481种肠杆菌科细菌中，在肠杆菌科分离株中，检测到49（10.19％）（7.50-12.90，95％置信区间）为氨苄酶Cβ-内酰胺酶生产者。
UNASSIGNED：氨苄酶Cβ-内酰胺酶生产者的患病率低于在类似环境中进行的其他研究。美罗培南可能是治疗由产生氨苄酶Cβ-内酰胺酶的革兰氏阴性菌引起的感染的首选药物。
未经批准：抗生素；β-内酰胺酶；肠杆菌科；革兰氏阴性菌。
UNASSIGNED：一项描述性横断面研究于2021年5月至2021年10月在三级护理中心的临床微生物学实验室进行。从机构审查委员会收到伦理批准(参考号:044-077/078)。通过方便取样收集来自各种临床样品的肠杆菌科分离物。使用头孢西丁（30μg）圆盘在肠杆菌科分离株中筛选β-内酰胺酶生产者。通过头孢西丁-氯唑西林双盘协同作用试验，在筛选阳性分离株中检测氨苄酶Cβ-内酰胺酶生产者。≥4mm的区域大小的增加被认为是氨苄酶Cβ-内酰胺酶的生产者。计算点估计和95%置信区间。
未经证实：在总共481种肠杆菌科细菌中，在肠杆菌科分离株中，检测到49（10.19％）（7.50-12.90，95％置信区间）为氨苄酶Cβ-内酰胺酶生产者。
UNASSIGNED：氨苄酶Cβ-内酰胺酶生产者的患病率低于在类似环境中进行的其他研究。美罗培南可能是治疗由产生氨苄酶Cβ-内酰胺酶的革兰氏阴性菌引起的感染的首选药物。
未经批准：抗生素；β-内酰胺酶；肠杆菌科；革兰氏阴性菌。
